NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Latigo Biotherapeutics LTGO

Latigo Biotherapeutics listed on Nasdaq on 7 Aug 2026 and is not in the S&P 500. It is worth $878 million. Its board is not in our data yet.

Listed
7 Aug 2026 on Nasdaq, IPO filings and terms
Headquarters
Thousand Oaks, CA
Market cap
$878M
19 Nov 2026 close
Revenue
-
No annual report yet

Board and leadership

Board and officers

Latigo Biotherapeutics's board is not in our data yet. It listed on 7 Aug 2026 and has not filed a proxy statement. See its 8-K filings.

Owners and trading

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers made no open-market sales and bought $2.5 million in 1 purchase in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
10 Aug 2026BuyJames B. TananbaumDirectorDirectorBuy140,000$2.5M

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

2 departures and 1 appointment of directors and officers in the last two years.

Left the company or board 2Appointed 1WARN layoff notices 0Large insider sales 0Jan 2025AprJulOctJan 2026AprJulOct

Events, newest first

Not on file: no weekly market cap history, no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no quarterly results in its SEC XBRL filings. 13F holdings: Latigo Biotherapeutics listed after the last quarter (30 Jun 2026). The next 13F filings were due by 14 Nov 2026.